Azenta Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Great. For our next panel here, we're going to do a presentation with Azenta. They're going to be diving into some of their genomics business. And representing Azenta today, we have Sara Silverman, who is Head of IR; and Andrea O'Hara, who is a technical specialist within the genomics business.
So Sara, I'll let you go ahead and get started here.
Okay. Great. Thanks, John. It's really great to be here at the UBS conference. We've had a great day of meetings, and we're really excited about this presentation we're about to do. So we're going to do an overview of the business as we typically do, but we're going to do something extra, a little special today. We have Andrea here, and she's going to do a deep dive into our genomics business.
I get the question a lot from investors, from analysts. They say, what about your genomics business is differentiated? How do you support the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |